[go: up one dir, main page]

MX2023006397A - Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. - Google Patents

Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.

Info

Publication number
MX2023006397A
MX2023006397A MX2023006397A MX2023006397A MX2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A
Authority
MX
Mexico
Prior art keywords
trem2
dysfunction
transporter
agonists
treatment
Prior art date
Application number
MX2023006397A
Other languages
English (en)
Inventor
Richard Fisher
Spyridon Papapetropoulos
Matthew Brennan
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of MX2023006397A publication Critical patent/MX2023006397A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del ABCD1 en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
MX2023006397A 2020-12-04 2021-12-06 Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. MX2023006397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121404P 2020-12-04 2020-12-04
PCT/US2021/072749 WO2022120390A1 (en) 2020-12-04 2021-12-06 Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists

Publications (1)

Publication Number Publication Date
MX2023006397A true MX2023006397A (es) 2023-08-11

Family

ID=81854825

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006397A MX2023006397A (es) 2020-12-04 2021-12-06 Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.

Country Status (11)

Country Link
US (2) US20230082623A1 (es)
EP (1) EP4255567A4 (es)
JP (1) JP2023552553A (es)
KR (1) KR20230130630A (es)
CN (1) CN117015400A (es)
AU (1) AU2021392813A1 (es)
CA (1) CA3203783A1 (es)
IL (1) IL303261A (es)
MX (1) MX2023006397A (es)
TW (1) TW202237186A (es)
WO (1) WO2022120390A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159055A1 (en) * 2019-11-22 2021-05-27 Forest Hoyt ANDREWS Trem2 antibodies and uses thereof
WO2024052343A1 (en) * 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
CN117534569A (zh) * 2023-11-23 2024-02-09 复旦大学附属华山医院 S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途
US12459953B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
TW202542156A (zh) 2024-01-04 2025-11-01 丹麥商穆納醫療有限責任公司 Ｔｒｅｍ２調節劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117069841A (zh) * 2015-10-06 2023-11-17 艾利妥 抗trem2抗体及其使用方法
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019068072A1 (en) * 2017-09-29 2019-04-04 The General Hospital Corporation METHODS OF IDENTIFICATION AND TREATMENT OF ADRENOMYELONEUROPATHY (AMN)
EP3732193A1 (en) * 2017-12-29 2020-11-04 Alector LLC Anti-tmem106b antibodies and methods of use thereof
CA3167851A1 (en) * 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法

Also Published As

Publication number Publication date
EP4255567A4 (en) 2024-11-20
EP4255567A1 (en) 2023-10-11
CN117015400A (zh) 2023-11-07
JP2023552553A (ja) 2023-12-18
WO2022120390A1 (en) 2022-06-09
AU2021392813A1 (en) 2023-06-29
KR20230130630A (ko) 2023-09-12
TW202237186A (zh) 2022-10-01
CA3203783A1 (en) 2022-06-09
US20250282866A1 (en) 2025-09-11
IL303261A (en) 2023-07-01
US20230082623A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
CR20230069A (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2
MX2023006397A (es) Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.
Zhao et al. Therapeutic potential of an anti-high mobility group box-1 monoclonal antibody in epilepsy
Potter et al. The effect of resveratrol on neurodegeneration and blood brain barrier stability surrounding intracortical microelectrodes
Verkhratsky et al. Physiology of astroglial excitability
Geppetti et al. Antidromic vasodilatation and the migraine mechanism
Chen et al. Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy
Ogawa et al. Peripherally administered orexin improves survival of mice with endotoxin shock
Matsuura et al. Mechanisms underlying ectopic persistent tooth-pulp pain following pulpal inflammation
RU2010108429A (ru) Регуляторы ммр-9 и их применение
Przeklasa-Muszyńska et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients
Zaytseva et al. Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors
Freise et al. Hepatic effects of thoracic epidural analgesia in experimental severe acute pancreatitis.
Park et al. Acute hypoglycemia causes depressive-like behaviors in mice
Gao et al. Dexmedetomidine alleviates anxiety-like behavior in mice following peripheral nerve injury by reducing the hyperactivity of glutamatergic neurons in the anterior cingulate cortex
Yu et al. Transcutaneous auricular vagal nerve stimulation inhibits limbic-regional P2X7R expression and reverses depressive-like behaviors in Zucker diabetic fatty rats
Wamil et al. Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons.
Shayan et al. Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or KATP channels inhibitors
Gur et al. Purinergic (P2) receptor control of lower genitourinary tract function and new avenues for drug action: an overview
Hu et al. Low-dose interleukin-2 and regulatory T cell treatments attenuate punctate and dynamic mechanical allodynia in a mouse model of sciatic nerve injury
UY39892A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
Chao et al. Attenuating ischemic disruption of K+ homeostasis in the cortex of hypoxic-ischemic neonatal rats: DOR activation vs. acupuncture treatment
US20190184015A1 (en) Irradiation treatment of neurological sensations by photoablation
Mirkin et al. The adrenergic nature of neurohumoral transmission in the cat nictitating membrane following treatment with reserpine
Ramkissoon et al. G protein-coupled receptors in haematopoietic disruption